Management of Migraine Treatment Failure

Current Treatment Assessment

The American College of Physicians recommends optimizing the acute treatment strategy while maintaining beneficial preventive therapy, such as lamotrigine, in patients with migraines 3

The American Academy of Neurology suggests switching from ubrogepant to a triptan medication, such as sumatriptan, rizatriptan, or zolmitriptan, as second-line therapy for acute migraine treatment, with strong recommendations supporting the use of triptans 2, 3, 4
The American Headache Society recommends taking triptans early in the headache phase for maximum effectiveness, with a strength of evidence rated as high 5

The American College of Physicians recommends adding an NSAID, such as ibuprofen or naproxen, to triptan therapy to enhance effectiveness and prevent recurrence, with moderate to high strength of evidence 1, 2, 3

The American Academy of Neurology suggests trying a different triptan if the first one is ineffective, as response to triptans can vary between patients, with a strength of evidence rated as moderate 1, 5
The American Headache Society recommends considering subcutaneous sumatriptan for attacks that rapidly reach peak intensity or when oral medications cannot be taken due to vomiting, with a strength of evidence rated as high 5

The American Academy of Neurology recommends continuing lamotrigine if it is providing benefit for migraine prevention, and considering adding or switching to a more evidence-based preventive option, such as CGRP monoclonal antibodies, if migraines remain inadequately controlled, with a strength of evidence rated as high 2, 4
The American Headache Society suggests that CGRP monoclonal antibodies, such as erenumab, fremanezumab, or galcanezumab, have strong evidence for prevention, with a strength of evidence rated as high 2, 4

The American Academy of Neurology recommends avoiding using acute medications more than twice weekly to prevent medication overuse headache, with a strength of evidence rated as high 1, 3
The American Headache Society suggests avoiding opioids and barbiturates for migraine treatment due to limited efficacy and risk of dependency, with a strength of evidence rated as high 3

The American College of Physicians recommends reassessing effectiveness of the new acute treatment after 2-4 weeks, with a strength of evidence rated as moderate 1
The American Academy of Neurology suggests documenting frequency, severity, and response to treatment to guide further management decisions, with a strength of evidence rated as moderate 1, 3